Compare VNRX & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNRX | ALLR |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5M | 19.3M |
| IPO Year | 2012 | 2021 |
| Metric | VNRX | ALLR |
|---|---|---|
| Price | $0.16 | $1.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $2.00 | ★ $9.75 |
| AVG Volume (30 Days) | ★ 17.2M | 106.7K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,727,384.00 | $320,000.00 |
| Revenue This Year | $479.89 | N/A |
| Revenue Next Year | $538.41 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 40.04 | N/A |
| 52 Week Low | $0.15 | $0.70 |
| 52 Week High | $0.94 | $2.35 |
| Indicator | VNRX | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 33.98 | 55.91 |
| Support Level | N/A | $0.98 |
| Resistance Level | $0.27 | $1.27 |
| Average True Range (ATR) | 0.02 | 0.08 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 5.66 | 69.31 |
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.